US Oncology Network Continues Its Rapid Growth and Enhances Surgical Expertise
April 2nd 2021The US Oncology Network, the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, continues to expand its reach into local communities while broadening its surgical expertise with the addition of physicians from Texas Colon & Rectal Specialists, a large colorectal practice in North Texas, as a part of Texas Oncology, a practice in The Network.
A Perfect Storm Brews for Biosimilar Marketing
October 3rd 2018Pressure to reduce costs associated with biologics is one of the forces driving the rapid expansion of biosimilars, which are biological drugs that are very similar to already approved reference biologics in terms of potency, safety, and efficacy.
Southern Cancer Center is Global Leader in Kidney Cancer Clinical Trial
Southern Cancer Center, a premier oncology clinic in Alabama and a practice in The US Oncology Network, is the first site in the world to open enrollment for a new clinical trial for newly diagnosed kidney cancer patients.
O'Shaughnessy Predicts Rapid Evolution in TNBC Landscape
February 6th 2017Joyce A. O’Shaughnessy, MD, addresses the key issues in breast cancer discussed at the 2017 OncLive® State of the Science Summit on Treatment of Metastatic Breast Cancer and shared her expert insight on where triple-negative breast cancer treatment is headed based on recent findings.
Dr. Kolibaba on Mechanism of Action With Entospletinib in MCL
December 23rd 2016Kathryn Kolibaba, MD, co-chair, Hematology Research Committee, US Oncology Research, discusses the mechanism of action with entospletinib (GS-9973) and its potential as a treatment for patients with mantle cell lymphoma (MCL).
Dr. Yasenchak on Brentuximab Vedotin Added to R-CHOP in DLBCL
February 17th 2016Christopher A. Yasenchak, MD, associate chair of Hematology Research, Willamette Valley Cancer Institute and Research Center/US Oncology Research, discusses results of a study examining the addition of brentuximab vedotin to R-CHOP for the treatment of patients with diffuse large B-cell lymphoma.
Compatibility Check: Can Precision Medicine and Pathways Co-Exist?
December 23rd 2015One of the most widely talked about trends in healthcare is precision medicine, which uses detailed genetic information about a patient’s cancer to more precisely treat the disease, effectively targeting the tumor. This heightened awareness raises an important question: are precision medicine and pathways compatible?